Goldman Sachs’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $51.1M | Sell |
1,719,721
-148,491
| -8% | -$4.44M | 0.01% | 1567 |
|
|
2025
Q4 | $71.4M | Buy |
1,868,212
+594,309
| +47% | +$19.3M | 0.01% | 1226 |
|
|
2025
Q3 | $30.4M | Sell |
1,273,903
-282,949
| -18% | -$5.32M | ﹤0.01% | 1854 |
|
|
2025
Q2 | $23M | Buy |
1,556,852
+689,210
| +79% | +$11.4M | ﹤0.01% | 2000 |
|
|
2025
Q1 | $15.5M | Sell |
867,642
-63,370
| -7% | -$1.29M | ﹤0.01% | 2273 |
|
|
2024
Q4 | $16.2M | Buy |
931,012
+228,406
| +33% | +$4.04M | ﹤0.01% | 2336 |
|
|
2024
Q3 | $9.83M | Sell |
702,606
-76,043
| -10% | -$792K | ﹤0.01% | 2751 |
|
|
2024
Q2 | $6.4M | Buy |
778,649
+59,782
| +8% | +$403K | ﹤0.01% | 2927 |
|
|
2024
Q1 | $5.54M | Sell |
718,867
-771,881
| -52% | -$6.51M | ﹤0.01% | 2999 |
|
|
2023
Q4 | $13.4M | Sell |
1,490,748
-21,339
| -1% | -$155K | ﹤0.01% | 2258 |
|
|
2023
Q3 | $13.5M | Buy |
1,512,087
+588,196
| +64% | +$8.3M | ﹤0.01% | 2136 |
|
|
2023
Q2 | $14.2M | Buy |
923,891
+132,663
| +17% | +$2.41M | ﹤0.01% | 2136 |
|
|
2023
Q1 | $17.8M | Sell |
791,228
-1,848,918
| -70% | -$39.3M | ﹤0.01% | 1914 |
|
|
2022
Q4 | $55.5M | Buy |
2,640,146
+86,172
| +3% | +$1.83M | 0.01% | 1094 |
|
|
2022
Q3 | $62.9M | Sell |
2,553,974
-58,672
| -2% | -$1.52M | 0.02% | 960 |
|
|
2022
Q2 | $63.3M | Buy |
2,612,646
+22,539
| +0.9% | +$567K | 0.02% | 968 |
|
|
2022
Q1 | $66.7M | Sell |
2,590,107
-3,650
| -0.1% | -$96.9K | 0.01% | 1049 |
|
|
2021
Q4 | $80.5M | Buy |
2,593,757
+1,500,435
| +137% | +$42.3M | 0.02% | 950 |
|
|
2021
Q3 | $26.5M | Sell |
1,093,322
-1,363,958
| -56% | -$25.1M | 0.01% | 1793 |
|
|
2021
Q2 | $35.9M | Buy |
2,457,280
+1,629,846
| +197% | +$32.1M | 0.01% | 1550 |
|
|
2021
Q1 | $20.7M | Buy |
827,434
+113,468
| +16% | +$3.14M | 0.01% | 1904 |
|
|
2020
Q4 | $19.5M | Buy |
713,966
+48,891
| +7% | +$1.14M | 0.01% | 1880 |
|
|
2020
Q3 | $12.3M | Sell |
665,075
-187,774
| -22% | -$3.65M | ﹤0.01% | 2146 |
|
|
2020
Q2 | $17.4M | Buy |
852,849
+149,359
| +21% | +$2.38M | 0.01% | 1802 |
|
|
2020
Q1 | $10.3M | Buy |
703,490
+578,306
| +462% | +$8.7M | ﹤0.01% | 2066 |
|
|
2019
Q4 | $1.78M | Buy |
125,184
+65,934
| +111% | +$842K | ﹤0.01% | 3728 |
|
|
2019
Q3 | $687K | Sell |
59,250
-341,004
| -85% | -$5.64M | ﹤0.01% | 4272 |
|
|
2019
Q2 | $8.04M | Sell |
400,254
-19,990
| -5% | -$395K | ﹤0.01% | 2526 |
|
|
2019
Q1 | $9.51M | Sell |
420,244
-151,126
| -26% | -$3.34M | ﹤0.01% | 2463 |
|
|
2018
Q4 | $12.9M | Sell |
571,370
-111,046
| -16% | -$2.76M | ﹤0.01% | 2154 |
|
|
2018
Q3 | $19.6M | Buy |
682,416
+148,276
| +28% | +$4.24M | 0.01% | 1939 |
|
|
2018
Q2 | $14.6M | Sell |
534,140
-566
| -0.1% | -$15.1K | ﹤0.01% | 2126 |
|
|
2018
Q1 | $12M | Sell |
534,706
-76,856
| -13% | -$1.83M | ﹤0.01% | 2204 |
|
|
2017
Q4 | $12.9M | Buy |
611,562
+17,255
| +3% | +$394K | ﹤0.01% | 2261 |
|
|
2017
Q3 | $14.8M | Buy |
594,307
+87,503
| +17% | +$1.93M | ﹤0.01% | 2241 |
|
|
2017
Q2 | $9.83M | Buy |
506,804
+182,880
| +56% | +$3.32M | ﹤0.01% | 2518 |
|
|
2017
Q1 | $5.98M | Sell |
323,924
-171,663
| -35% | -$3.36M | ﹤0.01% | 2794 |
|
|
2016
Q4 | $9.38M | Sell |
495,587
-44,651
| -8% | -$913K | ﹤0.01% | 2521 |
|
|
2016
Q3 | $12.1M | Sell |
540,238
-323,762
| -37% | -$6.16M | ﹤0.01% | 2299 |
|
|
2016
Q2 | $15.4M | Buy |
864,000
+41,573
| +5% | +$673K | 0.01% | 1987 |
|
|
2016
Q1 | $11.2M | Buy |
822,427
+302,245
| +58% | +$4.59M | ﹤0.01% | 2130 |
|
|
2015
Q4 | $10M | Buy |
520,182
+17,130
| +3% | +$342K | ﹤0.01% | 2244 |
|
|
2015
Q3 | $10.2M | Buy |
503,052
+487,267
| +3,087% | +$14.4M | ﹤0.01% | 2242 |
|
|
2015
Q2 | $523K | Sell |
15,785
-471,277
| -97% | -$12.9M | ﹤0.01% | 5158 |
|
|
2015
Q1 | $11.7M | Buy |
487,062
+278,263
| +133% | +$4.24M | ﹤0.01% | 2167 |
|
|
2014
Q4 | $2.56M | Buy |
208,799
+181,635
| +669% | +$1.88M | ﹤0.01% | 3599 |
|
|
2014
Q3 | $245K | Buy |
+27,164
| New | +$320K | ﹤0.01% | 5963 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Goldman Sachs's TVTX Position: Q1 2026 in Review
Goldman Sachs reduced its Travere Therapeutics (TVTX) stake by 7.9% in Q1 2026, selling an estimated $4.44M and leaving 1,719,721 shares worth $51.1M. The position accounts for 0.01% of the portfolio, ranked #1567.
Goldman Sachs first reported a position in TVTX in Q3 2014 and has held it in 47 quarters since. The position peaked at $80.5M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Goldman Sachs held 1,719,721 shares of Travere Therapeutics worth $51.1M as of Q1 2026.
- Goldman Sachs sold 148,491 Travere Therapeutics shares in Q1 2026, an estimated $4.44M.
- Travere Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1567 holding.
- Goldman Sachs first reported a position in Travere Therapeutics in Q3 2014 and has held it in 47 quarters since.
- Goldman Sachs's Travere Therapeutics position peaked at $80.5M in Q4 2021.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.